



August 01, 2025

**National Stock Exchange of India Limited,**  
Compliance Department,  
Exchange Plaza, Bandra Kurla Complex,  
Bandra (East), Mumbai - 400051,  
Maharashtra, India

**BSE Limited,**  
Compliance Department,  
Phiroze Jeejeebhoy Towers,  
Dalal Street, Mumbai - 400001,  
Maharashtra, India

Dear Sir/Madam,

**Subject : Press release**

**Stock Code : BSE – 539787, NSE – HCG**

We wish to inform you that the Board of Directors of the Company, at their meeting held on August 01, 2025, *inter alia*, has considered and approved the Unaudited Financial Results (Standalone and Consolidated) of the Company for the quarter ended June 30, 2025 (“Financial Results”).

We enclose herewith the communication being released to the Press on the Financial Results of the Company.

Request you to take this on record.

Thanking you,

**For HealthCare Global Enterprises Limited**

**Sunu Manuel**  
**Company Secretary & Compliance Officer**

**Encl: a/a.**

## HEALTHCARE GLOBAL ENTERPRISES LIMITED

Q1 FY26 Financial & Business Update

**Bangalore, 1<sup>st</sup> August 2025** – Healthcare Global Enterprises Limited (HCG), one of the largest provider of Cancer care in India under the brand “HCG” announced its Financial Results for the 1<sup>st</sup> Quarter ended 30<sup>th</sup> June 2025.

### REVENUE

**Rs. 6,132 Mn.**

 **+17%**

For Q1FY26 Y-o-Y

### Adjusted EBITDA\*

**Rs. 1,118 Mn.**

 **+20%**

For Q1FY26 Y-o-Y

### PROFIT AFTER TAX

**Rs. 47 Mn.**

 **-61%**

For Q1FY26 Y-o-Y

### REVENUE BREAKUP – HCG (ESTABLISHED vs EMERGING CENTERS)

Particulars (Rs. Mn.)	Q1FY26	Q1FY25	YoY
Established Centers	5,396	4,637	16%
Emerging Centers	587	475	24%

### EBITDA BREAKUP – HCG (ESTABLISHED vs EMERGING CENTERS)

Particulars (Rs. Mn.)	Q1FY26	Q1FY25	YoY
Established Centers	1,212	1,021	19%
Emerging Centers	78	42	85%

\*Adjusted EBITDA excludes ESOP is Rs 14.5 mn for Q1FY26 vs Rs. 19.5 mn for Q1FY25; One time cost for Q1FY26 is Rs 25.6mn

## Operational KPI's (Oncology)

Particulars	Q1FY26	Q1FY25
OPD Footfall ('000)	167	143
Chemo Sessions Administered ('000)	49	41
LINAC Capacity Utilizations (%)*	58%	65%
In-Patient Bed Occupancy (%)#	62%	61%

\*No of Linacs in Q1FY26 stands at 40 vs 36 in Q1FY25

(1 machine under transfer to other hospital, hence not counted for utilization. Total LINAC machine count remains 41 as on today)

#No of Operational beds in Q1FY26 stands at 1,486 vs 1,267 in Q1FY25

## OPERATIONAL HIGHLIGHTS for Q1FY26\*

- Revenue stood at Rs. 6,132 mn a growth of 17% Y-o-Y, driven by strong performance across key geographies including Ahmedabad, Kolkata, Nagpur and Mumbai
- Adj. EBITDA stood at Rs. 1,118 mn (20% Y-o-Y growth) with 18.2% EBITDA margin for Q1FY26 compared to Rs. 929 mn with 17.7% EBITDA margin in Q1FY25. Margin improvement driven by operating leverage in Emerging centers and continuous efforts in improving cost efficiencies
- OPD Volumes grew by 17% compared to same period last year and In-Patient bed occupancy stood at 62% in Q1FY26 compared to 61% in Q1FY25 despite operationalizing 219 additional beds
- LINAC capacity utilization on a like for like basis (i.e. for 36 LINACs) stood at 69% for Q1FY26 compared to 65% in Q1FY25
- Overall ARPOB stood at Rs. 44,751 vs. Rs. 44,342 in Q1FY25, a growth of 0.9%. Change in service mix for the quarter has led to increase in ALOS, thereby impacting ARPOB
- PAT for the quarter stood at Rs. 47.3 mn compared to Rs. 120.8 mn. Lower PAT on account of higher depreciation and interest expense from growth investments and acquisitions undertaken in the last year
- RoCE for established centers stood at 17.3% compared to 18.4% in Q1 FY25. The marginal decline is attributed to investments made towards expansion in Ahmedabad. Pre-corporate allocations, RoCE was 26.1%

\*Includes multi-specialty



**Commenting on the results, Dr. B.S. Ajaikumar, Founder and Non-Executive Chairman, HealthCare Global Enterprises Ltd. said,**

*“HCG continues to be on a strong growth trajectory, anchored by its leadership in cancer care, trusted brand, and commitment to clinical excellence. We remain focused on pioneering advanced technologies in India, including Cyclotron, Adaptive RT, CyberKnife, and AI-driven systems, while expanding capabilities in genomics and proteomics. Our integrated, multidisciplinary approach ensures that patients receive the right treatment the first time across our growing network.*

*With a solid foundation in place and a promising future ahead, I am pleased to welcome Dr. Manish Mattoo as our new Executive Director and Chief Executive Officer. The Board is confident that his proven leadership, strategic acumen, and healthcare experience will be instrumental in shaping HCG’s next phase of growth and driving long-term value for all stakeholders.”*

**Dr. Manish Mattoo, CEO HealthCare Global Enterprises Ltd. added,**

*“HCG has long stood as a beacon of excellence in cancer care, consistently setting new benchmarks in clinical innovation and outcomes. At the core of this success is its world-class team of oncologists, surgeons, and specialists, supported by a deeply ingrained culture of multidisciplinary collaboration and cutting-edge technology.*

*With a strong pan-India presence built over more than two decades, HCG ensures that high-quality and advanced cancer care is accessible to patients across the country. Clinically, HCG delivers consistent outcomes across its network, with performance metrics that are on par with some of the most reputed oncology centers in the world.*

*I am honored to join HCG, and it is a privilege to lead an organization that is transforming cancer care in India. I look forward to working closely with our teams to build on this remarkable legacy and drive the next phase of growth, innovation, and impact.”*



### **About Healthcare Global Enterprises Limited (HCG):**

HealthCare Global Enterprises Ltd. (HCG), headquartered in Bengaluru, is the largest provider of cancer care in India. Through its network of 22 comprehensive cancer centers across India and Africa, HCG has brought advanced cancer care to the doorstep of millions of people. HCG's comprehensive cancer centers provide expertise and advanced technologies for the effective diagnosis and treatment of cancer under one roof. Under the "Milann" brand, HCG operates 7 fertility centers.

### **Safe Harbor**

This document may contain forward-looking statements about Healthcare Global Enterprises Limited and its Subsidiaries, which are based on the beliefs, opinions, and expectations of the company's management as the date of this Investor release and the companies do not assume any obligation to update their forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change. These statements are not the guarantees of future performance and involve risks and uncertainties that are difficult to predict. Consequently, readers should not place any undue reliance on such forward-looking statements.

**For more information, please contact**

**Company : Healthcare Global Enterprises Limited**



CIN: L15200KA1998PLC023489

For updates and specific queries, please visit [www.hcgel.com](http://www.hcgel.com) or feel free to contact [investors@hcgoncology.com](mailto:investors@hcgoncology.com)

**Investor Relations : Strategic Growth Advisors**

**SGA** Strategic Growth Advisors

CIN: U74140MH2010PTC204285

Mr. Sagar Shroff – [sagar.shroff@sgapl.net](mailto:sagar.shroff@sgapl.net) / +91 98205 19303

Mr. Ayush Haria – [ayush.haria@sgapl.net](mailto:ayush.haria@sgapl.net) / +91 98204 62966